Glaucoma treatment. A review of people with primary open-angle glaucoma and ocular hypertension concluded that medical IOP lowering treatment slowed down the progression of visual field loss. Vascular flow and neurodegenerative theories of glaucomatous optic neuropathy have prompted studies on various neuroprotective therapeutic strategies, including nutritional compounds, some of which may be regarded by clinicians as safe for use now, while others are on trial. Intraocular pressure can be lowered with medication, usually eye drops. Several classes of medications are used to treat glaucoma, with several medications in each class. Each of these medicines may have local and systemic side effects.
Glaucoma valve drainage, such as iStent, CyPass, or Hydrus. A Cochrane Review of various aqueous shunts and modifications found that the Baerveldt implant may result in lower IOP than the Ahmed implant, but it was unclear if the difference in IOP reduction was clinically significant. The review suggests that practitioners should operate with the devices that they are most comfortable with, and have the most experience using. The glaucoma valve implant is indicated for glaucoma patients not responding to maximal medical therapy, with previous failed guarded filtering surgery (trabeculectomy) or in cases where conventional drainage surgery is unlikely to succeed. Common situations